Focused Investors LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)

Focused Investors LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,130,850 shares of the company's stock after selling 29,400 shares during the quarter. Johnson & Johnson accounts for about 6.0% of Focused Investors LLC's investment portfolio, making the stock its 5th largest holding. Focused Investors LLC's holdings in Johnson & Johnson were worth $187,540,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the fourth quarter worth $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth $33,000. Bernard Wealth Management Corp. acquired a new stake in Johnson & Johnson in the fourth quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson in the fourth quarter worth $38,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of research analyst reports. Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, June 5th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Finally, Morgan Stanley reaffirmed an "underperform" rating on shares of Johnson & Johnson in a report on Thursday, July 10th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $171.00.

Johnson & Johnson Stock Down 0.9%

Shares of Johnson & Johnson stock traded down $1.44 during trading on Tuesday, hitting $155.38. 6,860,493 shares of the stock traded hands, compared to its average volume of 8,081,524. The company has a fifty day moving average price of $153.79 and a two-hundred day moving average price of $154.63. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The stock has a market cap of $373.86 billion, a P/E ratio of 17.28, a PEG ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.